Cabenuva Dosage

 Recommended Adult Dosing

Dosage forms:  400 mg/600 mg convenience pack; 600 mg/900 mg convenience pack

Special Note

[400 mg/600 mg convenience pack components]

Info: pack contains cabotegravir 400 mg vial x1 and rilpivirine 600 mg vial x1

[600 mg/900 mg convenience pack components]

Info: pack contains cabotegravir 600 mg vial x1 and rilpivirine 900 mg vial x1

HIV infection

[qmo dosing regimen, cabotegravir component]

Dose: 600 mg IM x1, then 400 mg IM qmo; Start: on last day of current antiretroviral regimen or oral lead-in tx; Info: for pts w/ HIV-1 RNA <50 and no known tx failure or resistance to cabotegravir or rilpivirine; give w/ qmo rilpivirine IM injections; may give injections up to 7 days before or after scheduled dose; see pkg insert for dose recommendations for missed doses or switching to q2mo dosing regimen

[qmo dosing regimen, rilpivirine component]

Dose: 900 mg IM x1, then 600 mg IM qmo; Start: on last day of current antiretroviral regimen or oral lead-in tx; Info: for pts w/ HIV-1 RNA <50 and no known tx failure or resistance to cabotegravir or rilpivirine; give w/ qmo cabotegravir IM injections; may give injections up to 7 days before or after scheduled dose; see pkg insert for dose recommendations for missed doses or switching to q2mo dosing regimen

[q2mo dosing regimen, cabotegravir component]

Dose: 600 mg IM qmo x2 doses, then 600 mg IM q2mo; Start: on last day of current antiretroviral regimen or oral lead-in tx; Info: for pts w/ HIV-1 RNA <50 and no known tx failure or resistance to cabotegravir or rilpivirine; give w/ q2mo rilpivirine IM injections; may give injections up to 7 days before or after scheduled dose; see pkg insert for dose recommendations for missed doses or switching to qmo dosing regimens

[q2mo dosing regimen, rilpivirine component]

Dose: 900 mg IM qmo x2 doses, then 900 mg IM q2mo; Start: on last day of current antiretroviral regimen or oral lead-in tx; Info: for pts w/ HIV-1 RNA <50 and no known tx failure or resistance to cabotegravir or rilpivirine; give w/ q2mo cabotegravir IM injections; may give injections up to 7 days before or after scheduled dose; see pkg insert for dose recommendations for missed doses or switching to qmo dosing regimen

Renal dosing

CrCl >30: no adjustment; CrCl <30: not defined, caution advised

HD/PD: not defined, caution advised

Hepatic dosing

Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined

Recommended Peds Dosing

Dosage forms:  400 mg/600 mg convenience pack; 600 mg/900 mg convenience pack

Special Note

[400 mg/600 mg convenience pack components]

Info: pack contains cabotegravir 400 mg vial x1 and rilpivirine 600 mg vial x1

[600 mg/900 mg convenience pack components]

Info: pack contains cabotegravir 600 mg vial x1 and rilpivirine 900 mg vial x1

HIV infection

[qmo dosing regimen, cabotegravir component, 12 yo and older, >35 kg]

Dose: 600 mg IM x1, then 400 mg IM qmo; Start: on last day of current antiretroviral regimen or oral lead-in tx; Info: for pts w/ HIV-1 RNA <50 and no known tx failure or resistance to cabotegravir or rilpivirine; give w/ qmo rilpivirine IM injections; may give injections up to 7 days before or after scheduled dose; see pkg insert for dose recommendations for missed doses or switching to q2mo dosing regimen

[qmo dosing regimen, rilpivirine component, 12 yo and older, >35 kg]

Dose: 900 mg IM x1, then 600 mg IM qmo; Start: on last day of current antiretroviral regimen or oral lead-in tx; Info: for pts w/ HIV-1 RNA <50 and no known tx failure or resistance to cabotegravir or rilpivirine; give w/ qmo cabotegravir IM injections; may give injections up to 7 days before or after scheduled dose; see pkg insert for dose recommendations for missed doses or switching to q2mo dosing regimen

[q2mo dosing regimen, cabotegravir component, 12 yo and older, >35 kg]

Dose: 600 mg IM qmo x2 doses, then 600 mg IM q2mo; Start: on last day of current antiretroviral regimen or oral lead-in tx; Info: for pts w/ HIV-1 RNA <50 and no known tx failure or resistance to cabotegravir or rilpivirine; give w/ q2mo rilpivirine IM injections; may give injections up to 7 days before or after scheduled dose; see pkg insert for dose recommendations for missed doses or switching to qmo dosing regimens

[q2mo dosing regimen, rilpivirine component, 12 yo and older, >35 kg]

Dose: 900 mg IM qmo x2 doses, then 900 mg IM q2mo; Start: on last day of current antiretroviral regimen or oral lead-in tx; Info: for pts w/ HIV-1 RNA <50 and no known tx failure or resistance to cabotegravir or rilpivirine; give w/ q2mo cabotegravir IM injections; may give injections up to 7 days before or after scheduled dose; see pkg insert for dose recommendations for missed doses or switching to qmo dosing regimen

Renal dosing

CrCl >30: no adjustment; CrCl <30: not defined, caution advised

HD/PD: not defined, caution advised

Hepatic dosing

Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined